Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study

NCT02198664 ↗

Phase 2 Completed 47 enrolled Aimmune Therapeutics, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a multi-center, open-label, follow-on study to gather additional information on the safety and tolerability of oral desensitization with CPNA in the subjects who participated in ARC001.

Timeline

Start: 2014-08-27
Primary completion: 2018-01-04
Completion: 2018-01-04

Publications

Nilsson C, Scurlock AM, Dellon ES, Brostoff JM, Pham T, Ryan R, Brown KR, Adelman DC, Aceves SS. Onset of eosinophilic esophagitis during a clinical trial program of oral immunotherapy for peanut allergy. J Allergy Clin Immunol Pract. 2021 Dec;9(12):4496-4501. doi: 10.1016/j.jaip.2021.07.048. Epub 2021 Aug 11. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AR101	Protein / enzyme biologic	0.5 mg	Oral
Subject	AR101	Protein / enzyme biologic	1 mg	Oral
Subject	AR101	Protein / enzyme biologic	10 mg	Oral
Subject	AR101	Protein / enzyme biologic	100 mg	Oral
Subject	AR101	Protein / enzyme biologic	300 mg	Oral
Subject	AR101	Protein / enzyme biologic	475 mg	Oral
Subject	AR101	Protein / enzyme biologic	1000 mg	Oral

Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study

Summary

Timeline

Publications

Drugs

Indications